CellGenix, a global company providing GMP-grade raw materials for cell and gene therapy and tissue-engineered products, has appointed three experts in the field of cell and gene therapy to its Scientific Advisory Board.
The members of CellGenix’ Scientific Advisory Board are:
Cliona Rooney
Cliona Rooney, a Professor in the Center for Cell and Gene Therapy at Baylor College of Medicine. Rooney brings more than 20 years of expertise in the field of T cell immunotherapy for virus-associated diseases and cancer.
She was instrumental in the development of T-cell therapies virus-specific T-cells in the stem cell transplant setting and has further developed and refined antigen-specific T-cells for the treatment of cancer.
Her current interests are in gene modifications and other strategies to render T-cells effective within an immunosuppressive microenvironment.
Mitchell H. Finer
Mitchell H. Finer brings three decades of experience in the areas of regenerative medicine, cancer immunotherapy and cell and gene therapy, where he helped to advance products from conception through phase III clinical programmes.
Finer founded Oncorus and currently serves as CEO and CSO. In 2015 he joined MPM Capital as Managing Director and is a member of the Board of Directors of MPM portfolio company, Semma Therapeutics.
Prior to MPM, Finer served as CSO of bluebird bio, where he was responsible for strategic elaboration of bluebird’s gene-modified adult haematopoietic stem cell therapy business and led the development and partnering of CAR-T and genome engineering programmes.
Anthony Davies
Anthony Davies is the founder and Executive Chair of Dark Horse Consulting, a consultancy agency focused on CMC and product development issues in monoclonal antibody and cell and gene therapies.
Davies brings along more than two decades of experience in the cell and gene therapy field. During this period he has held positions of increasing responsibility at companies including Onyx Pharmaceuticals, Geron Corporation and Capricor.
